Evidence map›Paper›PMID 37151848›Full record

ArticleFASEB bioAdvances2023

Targeting XBP1 mRNA splicing sensitizes glioblastoma to chemotherapy.

Amiee Dowdell, Mark Marsland, Sam Faulkner, Craig Gedye, James Lynam, Cassandra P Griffin, Joanne Marsland, Chen Chen Jiang, Hubert Hondermarck

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FASEB bioAdvances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Amiee DowdellSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing University of Newcastle Callaghan New South Wales Australia.
Mark MarslandSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing University of Newcastle Callaghan New South Wales Australia.
Sam FaulknerSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing University of Newcastle Callaghan New South Wales Australia.ORCID https://orcid.org/0000-0002-4732-8252
Craig GedyeHunter Medical Research Institute University of Newcastle New Lambton Heights New South Wales Australia.
James LynamHunter Medical Research Institute University of Newcastle New Lambton Heights New South Wales Australia.
Cassandra P GriffinHunter Medical Research Institute University of Newcastle New Lambton Heights New South Wales Australia.
Joanne MarslandSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing University of Newcastle Callaghan New South Wales Australia.
Chen Chen JiangSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing University of Newcastle Callaghan New South Wales Australia.
Hubert HondermarckSchool of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing University of Newcastle Callaghan New South Wales Australia.
Hunter Medical Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is the most frequent and deadly primary brain tumor in adults. Temozolomide (TMZ) is the standard systemic therapy in GBM but has limited and restricted efficacy. Better treatments are urgently needed. The role of endoplasmic reticulum stress (ER stress) is increasingly described in GBM pathophysiology. A key molecular mediator of ER stress, the spliced form of the transcription factor x-box binding protein 1 (XBP1s) may constitute a novel therapeutic target; here we report XBP1s expression and biological activity in GBM. Tumor samples from patients with GBM (

Indexed as

cancer biomarkersglioblastomatherapeutic targetsXBP1s

Identifiers

PMID37151848
PMCPMC10158625
OpenAlexW4321788311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.